BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zile MR, Abraham WT, Lindenfeld J, Weaver FA, Zannad F, Graves T, Rogers T, Galle EG. First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. Am Heart J 2018;204:139-50. [PMID: 30118942 DOI: 10.1016/j.ahj.2018.07.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Fudim M, Abraham WT, von Bardeleben RS, Lindenfeld J, Ponikowski PP, Salah HM, Khan MS, Sievert H, Stone GW, Anker SD, Butler J. Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;78:931-56. [PMID: 34446165 DOI: 10.1016/j.jacc.2021.06.040] [Reference Citation Analysis]
2 Seravalle G, Dell’oro R, Grassi G. Baroreflex activation therapy systems: current status and future prospects. Expert Review of Medical Devices 2019;16:1025-33. [DOI: 10.1080/17434440.2019.1697230] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
3 Broglio K, Meurer WJ, Durkalski V, Pauls Q, Connor J, Berry D, Lewis RJ, Johnston KC, Barsan WG. Comparison of Bayesian vs Frequentist Adaptive Trial Design in the Stroke Hyperglycemia Insulin Network Effort Trial. JAMA Netw Open 2022;5:e2211616. [PMID: 35544137 DOI: 10.1001/jamanetworkopen.2022.11616] [Reference Citation Analysis]
4 Lohmeier TE, Hall JE. Device-Based Neuromodulation for Resistant Hypertension Therapy. Circ Res 2019;124:1071-93. [PMID: 30920919 DOI: 10.1161/CIRCRESAHA.118.313221] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
5 Mastoris I, Van Spall HGC, Sheldon SH, Pimentel RC, Steinkamp L, Shah Z, Al-Khatib SM, Singh JP, Sauer AJ. Emerging Implantable Device Technology for Patients at the Intersection of Electrophysiology and Heart Failure Interdisciplinary Care. J Card Fail 2021:S1071-9164(21)00465-6. [PMID: 34774748 DOI: 10.1016/j.cardfail.2021.11.006] [Reference Citation Analysis]
6 Januzzi JL Jr, Ibrahim NE. The Need to Innovate and Accelerate Clinical Trial Performance: BeAT the Clock. J Am Coll Cardiol 2020;76:14-6. [PMID: 32616157 DOI: 10.1016/j.jacc.2020.05.036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Blankart CR, Dams F, Penton H, Kaló Z, Zemplényi A, Shatrov K, Iskandar R, Federici C. Regulatory and HTA early dialogues in medical devices. Health Policy 2021:S0168-8510(21)00193-7. [PMID: 34353636 DOI: 10.1016/j.healthpol.2021.07.010] [Reference Citation Analysis]
8 Groenland EH, Spiering W. Baroreflex Amplification and Carotid Body Modulation for the Treatment of Resistant Hypertension. Curr Hypertens Rep 2020;22:27. [PMID: 32166464 DOI: 10.1007/s11906-020-1024-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Stavrakis S, Kulkarni K, Singh JP, Katritsis DG, Armoundas AA. Autonomic Modulation of Cardiac Arrhythmias: Methods to Assess Treatment and Outcomes. JACC Clin Electrophysiol 2020;6:467-83. [PMID: 32439031 DOI: 10.1016/j.jacep.2020.02.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
10 Johnston JL, Dhruva SS, Ross JS, Rathi VK. Early experience with the FDA’s Breakthrough Devices program. Nat Biotechnol 2020;38:933-8. [DOI: 10.1038/s41587-020-0636-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Zeitler EP, Abraham WT. Novel Devices in Heart Failure. JACC: Heart Failure 2020;8:251-64. [DOI: 10.1016/j.jchf.2019.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Malangu B, Lanier GM, Frishman WH. Nonpharmacologic Treatment for Heart Failure: A Review of Implantable Carotid Baroreceptor Stimulators As a Therapeutic Option. Cardiol Rev 2021;29:48-53. [PMID: 32282391 DOI: 10.1097/CRD.0000000000000307] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Zile MR, Lindenfeld J, Weaver FA, Zannad F, Galle E, Rogers T, Abraham WT. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology 2020;76:1-13. [DOI: 10.1016/j.jacc.2020.05.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
14 Barnes A, Campbell C, Weiss R, Kahwash R. Cardiac Contractility Modulation in Heart Failure: Mechanisms and Clinical Evidence. Curr Treat Options Cardio Med 2020;22. [DOI: 10.1007/s11936-020-00852-8] [Reference Citation Analysis]
15 Zannad F, Cotter G, Alonso Garcia A, George S, Davison B, Figtree G, Prasad K, Rockhold F, Schilsky RL, Stockbridge N, Pitt B, Butler J. What can heart failure trialists learn from oncology trialists? Eur Heart J 2021;42:2373-83. [PMID: 34076243 DOI: 10.1093/eurheartj/ehab236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]